ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 275

In Vitro Activation of Type I Interferon Pathway Reproduces the Characteristics Damages Observed in Dermatomyositis Patients

Leandro Ladislau1,2,3, Xavier Suárez-Calvet1,4, Claudia Benjamin3, Ségolène Toquet1, Benjamin Terrier5, Flore Rozenberg6, Vincent Mouly1, Gillian Butler Browne7, Werner Stenzel8, Olivier Benveniste9 and Yves Allenbach10, 1Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology., Paris, France, 2Programa de Ciências Biomédicas, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 3Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 4Neuromuscular Diseases Unit, Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona and Institut de Recerca Sant Pau., Barcelona, Spain, 5Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 6Departement de Virologie, Hôpital Cochin, Paris Descartes Universités, Paris, France, 7Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, 8Charité-Universitätsmedizin Berlin, Berlin, Germany, 9Pitié-Salpêtrière University Hospital, Paris, France, 10Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Angiogenesis, dermatomyositis, innate immunity, interferons and muscle biopsy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The type I interferons (IFN-I) including IFN-a, and IFN-b are key cytokines involved in innate immune response to viral infection. Almost all cells can produce IFN-I, express IFN-I receptor (IFNAR) and induce the transcription of IFN stimulated genes (ISGs), which have anti-proliferative and immunomodulatory activities. Idiopathic inflammatory myopathies (IIMs) are acquired auto-immune diseases. Among the IIMs, Dermatomyositis (DM) is characterized by skin lesions, muscle specific pathologic features combining inflammatory infiltration with HLA-ABC over-expression and vasculopathy. It is known that DM patients express up-regulated ISGs in muscle fibers, endothelial cells (EC), skin tissues and peripheral blood. However, the effect of the IFN-I on myoblasts (MB), myotubes (MT) and EC has not been well determined. Therefore, the aim of this study is to determine if MB, MT and EC present functional changes when exposed to IFN-I.

Methods:

The effect of the activation of IFN-I pathway on the differentiation of MB, and EC and on MT was analyzed in vitro. Thus, those cells were cultured with recombinant IFN-I, IFN-a, IFN-β and Poly (I:C) (PIC), an agonist of TLR3 receptor.

Results:

The results on MB showed that PIC, IFN-a and IFN-β abolished myotube formation and decreased myogenin (MyoG) expression. In differentiated MT, all stimuli induced ISGs (MxA and OAS1). Moreover, IFN-a, IFN-β and PIC dramatically reduced myotube surface. Next, IFN-a and IFN-b neutralization and IFNAR blocking experiments confirmed the specificity of the results. Neutralization and blocking experiments in differentiating MB treated with IFN-I, IFN-a and PIC, reverted the myotube formation and myogenin expression. Along the same lines, the surface area in differentiated MT area was restored. In addition, qPCR results showed the upregulation of genes involved in muscle atrophy such as Murf1 and Atrogin with a decrease of MyoG expression. The overexpression of Murf1 and atrogin was confirmed at the protein level in vivo, in muscle biopsies from DM patients. The presence of both proteins was detected in perifasicular areas, where atrophic fibers cluster. All stimuli induced HLA-ABC and TLR3 expression in differentiated MT and the presence of IFN-I in the supernatants in MB and MT. The activation of IFN-I pathway in EC, led to a decrease in cell proliferation and ISG up-regulation (MxA, RIG-I, ISG15 and TLR3). Tube formation assay with EC in the IFN-I-activated EC showed a disruption of the vascular network formation, indicating that IFN-I impairs angiogenesis in vitro.

Conclusion: In conclusion, in vitro treatment with IFN-I or IFN-I pathway activation recapitulates the characteristic pathological features (muscular and vascular damage) defining DM. This emphasizes the key role of the IFN-I pathway in the pathophysiology of DM, results that potentially may lead to new avenues for therapeutic approaches.


Disclosure: L. Ladislau, None; X. Suárez-Calvet, None; C. Benjamin, None; S. Toquet, None; B. Terrier, None; F. Rozenberg, None; V. Mouly, None; G. Butler Browne, None; W. Stenzel, None; O. Benveniste, None; Y. Allenbach, None.

To cite this abstract in AMA style:

Ladislau L, Suárez-Calvet X, Benjamin C, Toquet S, Terrier B, Rozenberg F, Mouly V, Butler Browne G, Stenzel W, Benveniste O, Allenbach Y. In Vitro Activation of Type I Interferon Pathway Reproduces the Characteristics Damages Observed in Dermatomyositis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/in-vitro-activation-of-type-i-interferon-pathway-reproduces-the-characteristics-damages-observed-in-dermatomyositis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-vitro-activation-of-type-i-interferon-pathway-reproduces-the-characteristics-damages-observed-in-dermatomyositis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology